Retrophin (RTRX) Setup Into DUET Data Remains Favorable - BMO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/16/2024
- Dow, S&P open higher as upbeat earnings obscure Mideast jitters
- UnitedHealth (UNH) beats earnings, revenue estimates in Q1; shares up
- Morgan Stanley (MS) earnings beat lifts stock
- Johnson & Johnson (JNJ) posts mixed results, narrows full-year guidance
- DOJ reportedly preparing antitrust lawsuit against Live Nation, shares slide 9%
- Trump Media & Technology Group (DJT) Files S-1
- Tesla (TSLA) Senior VP Drew Baglino Is Said To Leave The Company - Bloomberg
- General Motors (GM) Said to be Moving Detroit HQ to Dan Gilbert's Hudson Tower - Bloomberg
- The Israeli Air Force Has Completed Its Preparation For An Imminent Attack Against Iran - Reuters
- Biohaven Pharma (BHVN) presents update on degrader platform and summary of progress to date in Phase 1 single ascending dose study for BHV-1300
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
- After-hours movers: Tesla, Gildan Activewear, Macatawa Bank, and more
- Midday movers: Goldman Sachs and Meta Platforms rise; Apple and Tesla fall
- Nike, Alpine Immune Sciences rise premarket; CarMax, Robinhood and Regeneron fall
Retrophin (RTRX) Tops Q2 EPS by 16c
August 4, 2016 6:34 PM EDTRetrophin (NASDAQ: RTRX) reported Q2 EPS of ($0.07), $0.16 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $33.3 million versus the consensus estimate of $32.73 million.
We are very pleased with our strong second quarter performance, which was led by growth across... More
